Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1272. doi: 10.1164/rccm.201304-0712LE.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Clinical Trials, Phase III as Topic / methods*
  • Endpoint Determination / methods*
  • Humans
  • Idiopathic Pulmonary Fibrosis / drug therapy*
  • Respiratory System Agents / therapeutic use*

Substances

  • Respiratory System Agents